Molecular Templates, Inc. (MTEM)

NASDAQ: MTEM · IEX Real-Time Price · USD
2.90
0.04 (1.40%)
Jan 28, 2022 1:46 PM EST - Market open
Market Cap163.28M
Revenue (ttm)24.23M
Net Income (ttm)-101.21M
Shares Out56.31M
EPS (ttm)-1.88
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume65,040
Open2.87
Previous Close2.86
Day's Range2.76 - 2.94
52-Week Range2.76 - 15.19
Beta1.03
AnalystsStrong Buy
Price Target11.57 (+299.0%)
Earnings Daten/a

About MTEM

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. Its proprietary drug platform technology is engineered toxin bodies (ETBs). The company's lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed and refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma. It also develops MT-4019, engineered toxin body targeting CD38; TA...

IndustryBiotechnology
CEOEric Poma
Employees262
Stock ExchangeNASDAQ
Ticker SymbolMTEM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for MTEM stock is "Strong Buy." The 12-month stock price forecast is 11.57, which is an increase of 298.97% from the latest price.

Price Target
$11.57
(298.97% upside)
Analyst Consensus: Strong Buy

News

Molecular Templates Provides Corporate Update and Outlines 2022 Milestones

Unique PD-L1-mediated immune changes and early signs of anti-tumor activity with MT-6402

1 month ago - GlobeNewsWire

Molecular Templates Inc. (MTEM) Reports Q3 Loss, Misses Revenue Estimates

Molecular Templates Inc. (MTEM) delivered earnings and revenue surprises of -68.75% and -84.84%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the ...

2 months ago - Zacks Investment Research

Molecular Templates, Inc. Reports Third Quarter 2021 Financial Results

AUSTIN, Texas, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and devel...

2 months ago - GlobeNewsWire

Molecular Templates Inc. (MTEM) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Molecular Templates Inc. (MTEM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

4 Small Drug Stocks That Hold Promise Despite Industry Challenges

Some residual impact of the coronavirus pandemic is expected on the Medical-Drugs industry players' third-quarter results. XNCR, ENTA, CPRX and MTEM may prove to be good additions to one's portfolio.

Other symbols:CPRXENTAXNCR
3 months ago - Zacks Investment Research

Wall Street Analysts Predict a 98% Upside in Molecular Templates Inc. (MTEM): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 98.3% in Molecular Templates Inc. (MTEM). While the effectiveness of this highly sought-after metric is questiona...

3 months ago - Zacks Investment Research

Molecular Templates Inc. (MTEM) Moves 11.8% Higher: Will This Strength Last?

Molecular Templates Inc. (MTEM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pri...

4 months ago - Zacks Investment Research

Molecular Templates Inc. (MTEM) Reports Q2 Loss, Lags Revenue Estimates

Molecular Templates Inc. (MTEM) delivered earnings and revenue surprises of -115.38% and -50.65%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Molecular Templates, Inc. Reports Second Quarter 2021 Financial Results

AUSTIN, Texas, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and devel...

5 months ago - GlobeNewsWire

Molecular Templates Inc. (MTEM) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Molecular Templates Inc. (MTEM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Molecular Templates, Inc. Announces Dosing of First Subject in Phase 1 Study of MT-6402 in PD-L1-Positive Solid Tumors

AUSTIN, Texas, July 09, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and develo...

6 months ago - GlobeNewsWire

Molecular Templates Inc. (MTEM) Reports Q1 Loss, Lags Revenue Estimates

Molecular Templates Inc. (MTEM) delivered earnings and revenue surprises of -282.14% and -89.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Molecular Templates, Inc. Reports First Quarter 2021 Financial Results

AUSTIN, Texas, May 13, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and develo...

8 months ago - GlobeNewsWire

Molecular Templates Announces Poster Presentations on its Engineered Toxin Bodies at the American Association of Canc...

Posters will feature data on MT-5111 (targeting HER2), MT-6402 (targeting PD-L1) and a novel CTLA-4-targeted ETB Posters will feature data on MT-5111 (targeting HER2), MT-6402 (targeting PD-L1) and a no...

9 months ago - GlobeNewsWire

Why Molecular Templates Stock Crashed Today

The company is taking back rights to one drug candidate and discontinuing development of another.

9 months ago - The Motley Fool

Molecular Templates Stock Falls After It Stops MT-3724 Development In Hematological Malignancies

Molecular Templates Inc (NASDAQ: MTEM) has decided to discontinue the development of MT-3724, its only first-generation engineered toxin bodies (ETB), and focus its resources on the development of next-...

9 months ago - Benzinga

Molecular Templates to Prioritize Next-Generation ETB Candidates

Molecular Templates to Assume Full Rights to TAK-169, Second Generation ETB Targeting CD38 for the Treatment of Multiple Myeloma

9 months ago - GlobeNewsWire

Molecular Templates, Inc. Reports Fourth Quarter 2020 Financial Results

AUSTIN, Texas, March 18, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and deve...

10 months ago - GlobeNewsWire

The Past Week's Notable Insider Buys: Agree Realty, Avis Budget, Zoetis And More

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Returning buyers and chief executives were among the insiders making purchases this week.

11 months ago - Benzinga

The Past Week's Notable Insider Buys: More Biotech IPOs, Bumble, Fiserv And More

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Biotech stocks and secondary and initial public offerings were well represented this week.

11 months ago - Benzinga

Why Veru, Invitae And More Are Moving Today

Community Health Systems (NYSE: CYH) shares are trading higher after the company reported better-than-expected fourth-quarter sales results. Community Health Systems is the largest publicly owned hospit...

Other symbols:NVTAVERUCYH
11 months ago - Benzinga

Molecular Templates, Inc. Announces Proposed Public Offering of Common Stock

AUSTIN, Texas, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and developm...

11 months ago - GlobeNewsWire

Molecular Templates Establishes Multi-Target Collaboration With Bristol Myers Squibb for the Discovery and Developmen...

Molecular Templates to receive $70 million upfront payment with potential for additional milestone and royalty payments on future sales Molecular Templates to receive $70 million upfront payment with po...

11 months ago - GlobeNewsWire

Molecular Templates, Inc. Provides Update on MT-5111 Phase 1 Study

Phase 1 Study Dose Escalation Ongoing in All HER2 Positive Tumor Types HER2 Positive Breast Cancer Expansion Cohort Planned to be Initiated in 1H21 Expansion Cohorts in Additional Tumors Types to Begin ...

1 year ago - GlobeNewsWire

Molecular Templates to Participate in Upcoming Virtual Investor Conferences

AUSTIN, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and develo...

1 year ago - GlobeNewsWire